Study of Respiratory Physiology During High Flow Nasal Cannula Treatment in Preterm Neonates.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

45 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-08-31

Study Completion Date

2015-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The most commonly used noninvasive respiratory support in preterm babies is Continuous Positive Airway Pressure (CPAP), which provides extra breathing support to babies who are breathing by themselves). Increasingly High flow Nasal Cannula (HFNC, newer form of extra breathing support) therapy has found its way in clinical practice despite lack of good physiological data. There are also concerns about its potential to generate higher pressures in airways which can cause over distension of lungs.

We would like to find out the effects of HFNC on

* 1\. Airway pressures in various flow rates and in comparison to CPAP.
* 2\. Breathing markers including respiratory rate (speed of breathing), oxygen and carbon dioxide levels, tidal volumes (how much air breathed in with each breath) and airway wash out (wash out of waste gas from the airway).

We plan to study 15 babies each in three different weight categories supported with either CPAP or HFNC. The airway pressures, oxygen and carbon dioxide concentration in airway are measured by a small plastic catheter (similar to feeding tube but much shorter in length), carbon dioxide levels by skin sensors, how fast and how much babies breathe by a special vest applied like a layer of clothing. These will be recorded both on HFNC and CPAP. There are no blood tests or invasive procedures involved. The baby will be monitored throughout the study period of approximately two hours by experienced registrar who is trained to use the study device.

This study will improve our understanding of physiological effects of HFNC and lead to better care of preterm babies.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

High Flow Nasal Cannula Versus Bubble Nasal CPAP for the Treatment of Transient Tachypnea of the Newborn in Infants ≥ 35 Weeks Gestation

NCT01270581

Transient Tachypnea of the Newborn

TERMINATED NA

Changes in Respiratory Effort in Preterm Infants

NCT02014493

Premature Birth

COMPLETED NA

Infant Pulmonary Mechanics: High Flow Nasal Cannula Versus Nasal CPAP

NCT01939067

Respiratory Distress Lung Injury

WITHDRAWN PHASE1

HFNC and NCPAP in Extremely Preterm Infants

NCT03649282

Extreme Prematurity

COMPLETED NA

High Flow Nasal Cannula Versus Nasal Continuous Positive Airway Pressure for Respiratory Support of Preterm Neonates

NCT04238273

Respiratory Distress Syndrome, Newborn

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Purpose and design

Design: Prospective randomised crossover study.

Purpose:

* Raising airway pressure is one of the most important interventions at the disposal of clinicians treating patients with respiratory failure. In premature infants Continuous Positive Airway Pressure (CPAP) and High Flow Nasal Cannula (HFNC) are noninvasive techniques to raise mean airway pressure when intubation is not required. It is not clear how clinicians choose between these techniques and there is little data comparing the physiological effect of these treatments.
* A composite physiological assessment of babies on HFNC and CPAP treatment is required to understand how HFNC works. It is important to answer this question to understand how best to use HFNC in babies.
* This proposal is designed to provide information on physiological effects of both therapies in same population of babies across different weight categories. The study protocol involves use of same HFNC device that is currently being used in neonatal unit.

Interventions:

1\. A small plastic catheter tip transducer (Gaeltec) will be placed in upper breathing passage (nasopharynx or oropharynx) using standard methods. From this we will measure airway pressures and respiratory gas concentrations.

The catheter will be removed soon after the study is completed. This procedure will be done once during the study.

2\. Breathing markers (Tidal breathing indices) will be measured by non invasive method using Volusense method where a vest will be applied over the chest and abdomen like a layer of clothing. The Volusense vest will be removed soon after the procedure. This process is done once during the study.

3\. Blood carbon dioxide (CO2) levels will be measured by a non invasive transcutaneous sensor applied to the skin (Tosca Radiometer). This skin sensor will be removed soon after the study is completed.

1. The baby must be clinically stable for preceding 12 hours on noninvasive breathing support (not meeting exit criteria). The babies will be randomised to either group 1 (CPAP first followed by HFNC) or group 2 (HFNC first followed by CPAP) by computerised software programme.
2. The measuring devices namely nasopharyngeal catheter, Volusense vest and transcutaneous CO2 sensor are placed as per standard methods.
3. After ensuring babies' clinical stability the measurements are recorded at HFNC gas flow rate range from 2 litres to 8 litres per minute and in CPAP of 6 cm of water pressure level.
4. The study lasts about 2 hours. The baby spends 10 minutes at each HFNC flow rate level and 30 minutes of equilibration period when support will be changed between HFNC and CPAP.
5. Routine measurement of heart rate, respiratory rate and oxygen saturations will be done as per standard neonatal practice. The above data will be recorded electronically for analysis with total study duration around 120 minutes.
6. Respiratory support can be terminated at any point if clinically not indicated.

The researcher is an experienced neonatal registrar who will be directly observing the baby throughout the study.

Measurements would be discontinued if any pre set exit criteria is noted.

Statistics: A total of 45 babies (15 babies in each weight category: \<1000 grams, 1001500 grams and \>1500 grams) will be studied.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Extreme Prematurity - Less Than 28 Weeks Respiratory Distress Syndrome in Premature Infants

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1 ( CPAP followed by HFNC)

In this group pharyngeal pressure, transcutaneous carbon dioxide concentration, tidal volumes and pharyngeal gas concentrations will be recorded on CPAP first followed by HFNC.

Group Type ACTIVE_COMPARATOR

Pharyngeal pressure

Intervention Type OTHER

Babies will have pharyngeal pressures measured during the CPAP and HFNC respiratory support.

Transcutaneous carbon dioxide

Intervention Type OTHER

Babies will have transcutaneous carbon dioxide measured during CPAP and HFNC respiratory support.

Pharyngeal gas concentrations

Intervention Type OTHER

Measurement of pharyngeal oxygen and carbon dioxide concentration will be done during CPAP and HFNC respiratory support.

Tidal volume

Intervention Type OTHER

Tidal breathing indices including tidal volume and FRC base line changes will be recorded during CPAP and HFNC respiratory support.

Group 2 (HFNC followed by CPAP)

In this group pharyngeal pressure, transcutaneous carbon dioxide concentration, tidal volumes and pharyngeal gas concentrations will be recorded on HFNC first followed by CPAP.

Group Type ACTIVE_COMPARATOR

Pharyngeal pressure

Intervention Type OTHER

Babies will have pharyngeal pressures measured during the CPAP and HFNC respiratory support.

Transcutaneous carbon dioxide

Intervention Type OTHER

Babies will have transcutaneous carbon dioxide measured during CPAP and HFNC respiratory support.

Pharyngeal gas concentrations

Intervention Type OTHER

Measurement of pharyngeal oxygen and carbon dioxide concentration will be done during CPAP and HFNC respiratory support.

Tidal volume

Intervention Type OTHER

Tidal breathing indices including tidal volume and FRC base line changes will be recorded during CPAP and HFNC respiratory support.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pharyngeal pressure

Babies will have pharyngeal pressures measured during the CPAP and HFNC respiratory support.

Intervention Type OTHER

Transcutaneous carbon dioxide

Babies will have transcutaneous carbon dioxide measured during CPAP and HFNC respiratory support.

Intervention Type OTHER

Pharyngeal gas concentrations

Measurement of pharyngeal oxygen and carbon dioxide concentration will be done during CPAP and HFNC respiratory support.

Intervention Type OTHER

Tidal volume

Tidal breathing indices including tidal volume and FRC base line changes will be recorded during CPAP and HFNC respiratory support.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* They are less than 37 weeks' gestation at birth and more than 5 days of age
* Are on non-invasive respiratory support and
* The parent(s) have given written informed consent to their baby's participation

Exclusion Criteria

* Infants who are clinically unstable and unsuitable for non-invasive respiratory support as judged by attending neonatology consultant clinician.
* Participation in a concurrent study that prohibits inclusion in other trials
* Known major upper airway, lower respiratory tract, cardiac or gastrointestinal tract anomaly
* Current complications such as pneumothorax.

Minimum Eligible Age

5 Days

Maximum Eligible Age

4 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

No